The study is planned in two parts. In the first part, maribavir is taken for about 6 months. If the virus level drops but does not fall enough, treatment may continue for about 3 more months. During the study, the health of the participants and the amount of virus in the body are followed over time, along with whether the virus comes back after treatment is stopped.

Epstein-Barr virus is a common virus that can stay active in the body after infection. In people who have had a kidney transplant, the immune system is weakened to protect the new organ, and this can make it harder to control the virus. Maribavir is an antiviral medicine, which means it is designed to stop a virus from making more copies of itself.

The purpose of the study is to evaluate the safety and how well participants tolerate a step‑up dosing schedule of 25 mg, then 50 mg, and finally 100 mg of the drug. Volunteers will take the tablet at each dose level for a short period, after which they will provide saliva samples to check for the amount of virus present and have blood drawn to measure immune responses such as the number of CD4 T cells that react to the virus using a test called ELISPOT, as well as levels of specific antibodies, including IgG. The study proceeds without complex procedures, allowing participants to continue their normal daily activities while being monitored for any side effects.

Participants in the study will be randomly assigned to receive either the 2LEBV treatment, the 2LXFS treatment, or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving which treatment. This helps ensure that the results are not biased. The study will last for a period of six months, during which participants will take the treatment as directed and attend regular check-ups to monitor their progress and any changes in their symptoms.

The main goal of the study is to assess the severity of fatigue at the end of the treatment period. Participants will complete questionnaires to evaluate their level of fatigue and other related symptoms. The study will also monitor the safety of the treatments by recording any side effects that occur. By the end of the study, researchers hope to determine whether 2LEBV or 2LXFS can effectively reduce fatigue in patients with an EBV infection compared to a placebo.

Participants in the study will be randomly assigned to one of two groups. One group will receive Rituximab, which is a type of medication known as a monoclonal antibody that targets specific cells in the immune system. The other group will receive a placebo. The study will monitor the participants over a period of time to observe the incidence of EBV infection and PTLD, as well as other health outcomes related to the transplant.

The study will track various health indicators over several years, including the presence of EBV in the blood, kidney function, and any other infections or complications that may arise. The aim is to gather information on how effective Rituximab is in preventing these issues in kidney transplant patients who are at risk of EBV infection. This research could provide valuable insights into improving the care and outcomes for transplant recipients.

The purpose of the study is to assess how well the T cell treatment works in clearing the viral infections in patients who have not responded to other treatments. Participants in the study will receive the T cell treatment through an infusion, which is a method of delivering the treatment directly into the bloodstream. The study will monitor the patients over a period of time to see if the viral infections are reduced or cleared and to observe any side effects or changes in health status.

Throughout the study, various health indicators will be checked, such as the presence of the virus in the blood and any symptoms related to the infections. The study will also look at the overall health and survival of the patients, as well as any potential side effects from the treatment. The goal is to determine if the T cell treatment can provide a new option for patients with these challenging viral infections after stem cell transplantation.